Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rimegepant Sulfate

FDA-approved product (tablet, orally disintegrating, oral), marketed as Nurtec Odt.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rimegepant Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Migraine disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Calcitonin gene-related peptide (cgrp) antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rimegepant Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rimegepant Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

    NCT06680206 · start 2024-10-10

    Registered record
    Registry ID
    NCT06680206
    Conditions
    Migraine
    Interventions
    Rimegepant; Triptans
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-10-10
    Completion
    2024-11-20
    Enrolment
    1,395

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant; Triptans
    PhaseNot recorded
    Registry statusCompleted

  • A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache

    NCT06473597 · start 2024-09-01

    Registered record
    Registry ID
    NCT06473597
    Conditions
    Migraine
    Interventions
    Rimegepant; Rizatriptan Benzoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-09-01
    Completion
    2026-12-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant; Rizatriptan Benzoate
    PhasePhase 4
    Registry statusRecruiting

  • ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine

    NCT06439628 · start 2024-08-27

    Registered record
    Registry ID
    NCT06439628
    Conditions
    Migraine
    Interventions
    Rimegepant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-08-27
    Completion
    2027-06-28
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant
    PhaseNot recorded
    Registry statusActive not recruiting

  • Comparison of Rimegepant and Placebo for Pain in IBS

    NCT06221111 · start 2024-06-06

    Registered record
    Registry ID
    NCT06221111
    Conditions
    Irritable Bowel Syndrome
    Interventions
    Rimegepant 75 MG [Nurtec]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-06-06
    Completion
    2025-06-03
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritable Bowel Syndrome
    InterventionRimegepant 75 MG [Nurtec]
    PhasePhase 2
    Registry statusCompleted

  • Migraine Medication Effects on Urinary Symptoms

    NCT06212661 · start 2024-04-05

    Registered record
    Registry ID
    NCT06212661
    Conditions
    Overactive Bladder; Bladder Pain Syndrome; Migraine Disorders; Overactive Bladder Syndrome; Overactive Detrusor; Migraine; Interstitial Cystitis
    Interventions
    Ubrogepant; Rimegepant; Atogepant; Eptinezumab; Fremanezumab; Galcanezumab; Erenumab; Botulinum toxin A
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Enrolling by invitation
    Start
    2024-04-05
    Completion
    2026-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder; Bladder Pain Syndrome; Migraine Disorders; Overactive Bladder Syndrome +3 more
    InterventionUbrogepant; Rimegepant; Atogepant; Eptinezumab +4 more
    PhaseNot recorded
    Registry statusEnrolling by invitation

  • RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

    NCT06409832 · start 2024-03-26

    Registered record
    Registry ID
    NCT06409832
    Conditions
    Migraine; Migraine With Aura; Migraine Without Aura
    Interventions
    Rimegepant 75 mg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-03-26
    Completion
    2027-09
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Migraine With Aura; Migraine Without Aura
    InterventionRimegepant 75 mg
    PhaseNot recorded
    Registry statusRecruiting

  • A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area

    NCT06221267 · start 2024-01-26

    Registered record
    Registry ID
    NCT06221267
    Conditions
    Migraine
    Interventions
    Rimegepant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-01-26
    Completion
    2024-06-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

    NCT05810038 · start 2023-05-15

    Registered record
    Registry ID
    NCT05810038
    Conditions
    Migraine
    Interventions
    Rimegepant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-05-15
    Completion
    2025-12-10
    Enrolment
    787

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Prospective Real World Study of Rimegepant in the Treatment of Migraine

    NCT05709106 · start 2023-01-11

    Registered record
    Registry ID
    NCT05709106
    Conditions
    Migraine
    Interventions
    Rimegepant 75 MG
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-01-11
    Completion
    2025-04-09
    Enrolment
    173

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant 75 MG
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

    NCT05518123 · start 2022-11-07

    Registered record
    Registry ID
    NCT05518123
    Conditions
    Migraine
    Interventions
    Rimegepant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-11-07
    Completion
    2025-07-08
    Enrolment
    962

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

    NCT05509400 · start 2022-10-18

    Registered record
    Registry ID
    NCT05509400
    Conditions
    Migraine
    Interventions
    Rimegepant; Placebo; Rimegepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-10-18
    Completion
    2025-06-10
    Enrolment
    813

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant; Placebo; Rimegepant
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

    NCT05399459 · start 2022-08-09

    Registered record
    Registry ID
    NCT05399459
    Conditions
    Migraine
    Interventions
    Rimegepant 25 MG; Rimegepant 75 MG; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-08-09
    Completion
    2024-01-19
    Enrolment
    897

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant 25 MG; Rimegepant 75 MG; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)

    NCT05399485 · start 2022-08-09

    Registered record
    Registry ID
    NCT05399485
    Conditions
    Migraine
    Interventions
    Rimegepant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-08-09
    Completion
    2024-11-07
    Enrolment
    496

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRimegepant; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants

    NCT05371652 · start 2022-05-19

    Registered record
    Registry ID
    NCT05371652
    Conditions
    Acute Migraine
    Interventions
    Rimegepant 75mg Orally Disintegrating Tablets (ODT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-05-19
    Completion
    2024-02-06
    Enrolment
    241

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Migraine
    InterventionRimegepant 75mg Orally Disintegrating Tablets (ODT)
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine

    NCT05211154 · start 2022-05-05

    Registered record
    Registry ID
    NCT05211154
    Conditions
    Migraine With Aura; Migraine Without Aura
    Interventions
    Diclofenac Potassium 50Mg/Pkt Oral Pwdr; Rimegepant 75 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2022-05-05
    Completion
    2025-04-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine With Aura; Migraine Without Aura
    InterventionDiclofenac Potassium 50Mg/Pkt Oral Pwdr; Rimegepant 75 MG
    PhasePhase 4
    Registry statusTerminated